Cubist Systematic Strategies’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-69,908
| Closed | -$315K | – | 3650 |
|
|
2025
Q2 | $315K | Sell |
69,908
-85,614
| -55% | -$385K | ﹤0.01% | 2449 |
|
|
2025
Q1 | $689K | Buy |
155,522
+107,511
| +224% | +$624K | ﹤0.01% | 2018 |
|
|
2024
Q4 | $376K | Buy |
+48,011
| New | +$585K | ﹤0.01% | 2301 |
|
|
2024
Q3 | – | Sell |
-6,597
| Closed | -$79.7K | – | 3575 |
|
|
2024
Q2 | $79.7K | Sell |
6,597
-71,189
| -92% | -$961K | ﹤0.01% | 2657 |
|
|
2024
Q1 | $1.26M | Buy |
77,786
+40,674
| +110% | +$548K | 0.01% | 1984 |
|
|
2023
Q4 | $253K | Buy |
37,112
+559
| +2% | +$3.23K | ﹤0.01% | 2871 |
|
|
2023
Q3 | $199K | Sell |
36,553
-101,995
| -74% | -$594K | ﹤0.01% | 2788 |
|
|
2023
Q2 | $941K | Buy |
138,548
+81,523
| +143% | +$611K | 0.01% | 1990 |
|
|
2023
Q1 | $286K | Buy |
57,025
+17,866
| +46% | +$72.9K | ﹤0.01% | 3029 |
|
|
2022
Q4 | $191K | Buy |
39,159
+29,159
| +292% | +$212K | ﹤0.01% | 3603 |
|
|
2022
Q3 | $144K | Sell |
10,000
-542
| -5% | -$8.98K | ﹤0.01% | 3895 |
|
|
2022
Q2 | $160K | Sell |
10,542
-2,241
| -18% | -$26.1K | ﹤0.01% | 3789 |
|
|
2022
Q1 | $152K | Buy |
+12,783
| New | +$131K | ﹤0.01% | 3125 |
|
|
2021
Q4 | – | Sell |
-14,884
| Closed | -$425K | – | 3666 |
|
|
2021
Q3 | $425K | Buy |
+14,884
| New | +$469K | 0.01% | 2144 |
|
|
2021
Q1 | – | Sell |
-5,356
| Closed | -$265K | – | 2997 |
|
|
2020
Q4 | $265K | Buy |
+5,356
| New | +$248K | ﹤0.01% | 2101 |
|
|
2019
Q3 | – | Sell |
-520
| Closed | -$12K | – | 2523 |
|
|
2019
Q2 | $12K | Buy |
+520
| New | +$11.9K | ﹤0.01% | 2400 |
|
|
2018
Q4 | – | Sell |
-2,082
| Closed | -$55K | – | 2308 |
|
|
2018
Q3 | $55K | Buy |
+2,082
| New | +$52.9K | ﹤0.01% | 1695 |
|
Other funds holding YMAB
Cubist Systematic Strategies's YMAB Position: Q3 2025 in Review
Cubist Systematic Strategies sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 69,908 shares — an estimated $315K sold.
Cubist Systematic Strategies first reported a position in YMAB in Q3 2018 and held it in 17 quarters. The position peaked at $1.26M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Cubist Systematic Strategies reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 69,908 Y-mAbs Therapeutics shares in Q3 2025, an estimated $315K.
- Cubist Systematic Strategies first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 17 quarters.
- Cubist Systematic Strategies's Y-mAbs Therapeutics position peaked at $1.26M in Q1 2024.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.